Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ISC004
MIFTS: 61

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ischemia

About this section

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 54 44 15 17 71
Acute Coronary Syndrome 71

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:326
MeSH 44 D007511
NCIt 50 C34738
SNOMED-CT 67 52674009
UMLS 71 C0022116 C0948089
Sources

Summaries for Ischemia

About this section
Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to limb ischemia and retinal ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000284946 (), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Development Angiotensin activation of ERK. The drugs Simvastatin and Tirofiban have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone marrow and heart, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 74 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Sources

Related Diseases for Ischemia

About this section

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1592)
# Related Disease Score Top Affiliating Genes
1 limb ischemia 33.3 VEGFA NOS3 HIF1A CXCL12 ACE
2 retinal ischemia 33.1 VEGFA SOD1 HIF1A CXCL12 CASP3
3 transient cerebral ischemia 33.0 SOD2 CDK5 CASP3
4 vascular disease 32.6 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
5 lipoprotein quantitative trait locus 32.6 VEGFA PON1 NOS3 HIF1A CASP3 ADORA1
6 myocardial stunning 32.4 SOD1 ADORA3 ADORA1 ACE
7 nonarteritic anterior ischemic optic neuropathy 32.3 VEGFA NOS3 ACE
8 ischemic colitis 32.3 VEGFA HMOX1 HIF1A ACE
9 myocardial infarction 32.2 VEGFA PON1 NOS3 HMOX1 HIF1A EPO
10 microvascular complications of diabetes 5 32.2 VEGFA SOD2 PON1 NOS3 HIF1A CXCL12
11 exudative vitreoretinopathy 1 32.1 VEGFA NOS3 HIF1A EPO
12 brain edema 32.1 VEGFA SOD1 HMOX1
13 microvascular complications of diabetes 2 32.1 EPO ACE
14 microvascular complications of diabetes 1 32.1 VEGFA HIF1A EPO CXCL12
15 coronary stenosis 32.0 PON1 CXCL12 ACE
16 peripheral artery disease 31.9 VEGFA NOS3 HMOX1 HIF1A ACE
17 hyperglycemia 31.9 SOD2 SOD1 PRKAA2 NOS3 HIF1A
18 respiratory failure 31.8 VEGFA SOD1 EPO ACE
19 anoxia 31.8 SOD1 ADORA1
20 testicular torsion 31.8 NOS3 CASP3 ACE
21 pulmonary edema 31.7 NOS3 HMOX1 HIF1A EPO ACE
22 arteriosclerosis 31.6 PON1 NOS3 HMOX1 HIF1A CXCL12 ACE
23 end stage renal disease 31.6 VEGFA SOD2 PON1 NOS3 EPO ACE
24 carotid stenosis 31.6 VEGFA NOS3 ACE
25 chronic kidney disease 31.6 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
26 atherosclerosis susceptibility 31.6 VEGFA PON1 NOS3 ACE
27 pre-eclampsia 31.5 VEGFA SOD1 PON1 NOS3 HMOX1 HIF1A
28 congestive heart failure 31.5 VEGFA NOS3 EPO ADORA1 ACE
29 kidney disease 31.5 VEGFA PON1 NOS3 HMOX1 EPO ACE
30 retinal vascular disease 31.4 VEGFA NOS3 HIF1A CASP3 ACE
31 stroke, ischemic 31.4 SOD2 PON1 NOS3 CXCL12 CASP3 ADORA3
32 vascular dementia 31.4 VEGFA SOD1 PON1 CASP3 APP ACE
33 pheochromocytoma 31.3 VEGFA SOD1 HIF1A EPO EGR1 CASP3
34 heart disease 31.3 VEGFA SOD2 SOD1 PON1 NOS3 HMOX1
35 retinal artery occlusion 31.3 VEGFA HMOX1 ACE
36 macular retinal edema 31.2 VEGFA CXCL12 ACE
37 retinal vein occlusion 31.2 VEGFA CXCL12 ACE
38 pulmonary hypertension 31.2 VEGFA NOS3 HMOX1 HIF1A CASP3 ACE
39 diabetes mellitus 31.2 VEGFA SOD2 SOD1 PON1 NOS3 MAPK8IP1
40 sleep apnea 31.2 VEGFA NOS3 HIF1A EPO ACE
41 eclampsia 31.2 VEGFA NOS3 ACE
42 type 2 diabetes mellitus 31.2 VEGFA SOD2 SOD1 PRKAA2 PON1 NOS3
43 diabetic neuropathy 31.2 VEGFA SOD2 EPO ACE
44 aging 31.1 SOD2 HIF1A APP
45 renovascular hypertension 31.1 SOD1 NOS3 HMOX1 ACE
46 neuroblastoma 31.1 VEGFA SOD1 HMOX1 HIF1A EGR1 CXCL12
47 sickle cell disease 31.1 NOS3 HMOX1 EPO
48 deficiency anemia 31.1 SOD1 PON1 HMOX1 HIF1A EPO ACE
49 hydrocephalus 31.0 VEGFA CASP3 APP ACE
50 orthostatic intolerance 31.0 NOS3 EPO ACE

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia
Sources

Symptoms & Phenotypes for Ischemia

About this section

UMLS symptoms related to Ischemia:


muscle weakness, polydipsia, angina pectoris, anoxemia

MGI Mouse Phenotypes related to Ischemia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADORA1 ADORA3 APP CASP3 CXCL12
2 behavior/neurological MP:0005386 10.45 ACE ADORA1 ADORA3 APP CASP3 CDK5
3 homeostasis/metabolism MP:0005376 10.44 ACE ADORA1 ADORA3 APP CASP3 CDK5
4 cellular MP:0005384 10.4 APP CASP3 CXCL12 EGR1 EPO HIF1A
5 hematopoietic system MP:0005397 10.37 ACE ADORA3 APP CASP3 CXCL12 EGR1
6 growth/size/body region MP:0005378 10.35 ACE ADORA1 APP CASP3 EGR1 HIF1A
7 immune system MP:0005387 10.34 ACE ADORA3 APP CASP3 CXCL12 EGR1
8 mortality/aging MP:0010768 10.28 ACE ADORA1 APP CASP3 CDK5 CXCL12
9 endocrine/exocrine gland MP:0005379 10.25 ACE CASP3 EGR1 HIF1A HMOX1 MAPK8IP1
10 integument MP:0010771 10.22 ADORA1 ADORA3 APP CASP3 CDK5 EGR1
11 liver/biliary system MP:0005370 10.17 ACE CXCL12 EGR1 EPO HIF1A HMOX1
12 nervous system MP:0003631 10.17 ACE ADORA1 APP CASP3 CDK5 CXCL12
13 muscle MP:0005369 10.11 APP CASP3 CXCL12 EPO HIF1A HMOX1
14 limbs/digits/tail MP:0005371 10 APP EGR1 EPO HIF1A HMOX1 NOS3
15 renal/urinary system MP:0005367 9.96 ACE ADORA1 ADORA3 CASP3 HIF1A HMOX1
16 reproductive system MP:0005389 9.9 ACE APP CASP3 CXCL12 EGR1 HMOX1
17 respiratory system MP:0005388 9.65 ADORA1 ADORA3 CASP3 CDK5 EGR1 EPO
18 vision/eye MP:0005391 9.28 ACE ADORA3 CASP3 EGR1 HIF1A NOS3
Sources

Drugs & Therapeutics for Ischemia

About this section

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 810)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Tirofiban Approved Phase 4 144494-65-5 60947
3
Warfarin Approved Phase 4 81-81-2 6691 54678486
4
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
5
Zolpidem Approved Phase 4 82626-48-0 5732
6
Promethazine Approved, Investigational Phase 4 60-87-7 4927
7
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
8
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
9
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
12
Etomidate Approved Phase 4 33125-97-2 36339 667484
13
Nadroparin Approved, Investigational Phase 4
14
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
15
Insulin glargine Approved Phase 4 160337-95-1
16
Tocopherol Approved, Investigational Phase 4 1406-66-2
17
Enoxaparin Approved Phase 4 9005-49-6 772
18
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
19
Famotidine Approved Phase 4 76824-35-6 3325
20
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
21
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
22
Ezetimibe Approved Phase 4 163222-33-1 150311
23
Fondaparinux Approved, Investigational Phase 4 104993-28-4
24
Metformin Approved Phase 4 657-24-9 14219 4091
25
Acetaminophen Approved Phase 4 103-90-2 1983
26
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
29
Streptokinase Approved, Investigational Phase 4 9002-01-1
30
Pravastatin Approved Phase 4 81093-37-0 54687
31
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
32
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Glyburide Approved Phase 4 10238-21-8 3488
35
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
36
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
37
Abciximab Approved Phase 4 143653-53-6
38
Citalopram Approved Phase 4 59729-33-8 2771
39
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
40
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
41
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
42
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
43
Polyestradiol phosphate Approved Phase 4 28014-46-2
44
Ramipril Approved Phase 4 87333-19-5 5362129
45
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
46
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
47
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
48
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
49
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
50
Hydroxychloroquine Approved Phase 4 118-42-3 3652

Interventional clinical trials:

(show top 50) (show all 5502)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
3 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
4 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
5 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
6 A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome Unknown status NCT03007524 Phase 4 High dose Rosuvastatin;Low dose Rosuvastatin
7 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
8 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
9 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
10 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
11 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
12 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
13 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
14 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
15 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
16 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
17 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
18 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
19 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
20 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker
21 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
22 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
23 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
24 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
25 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II） Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
26 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
27 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAXâ„¢ Bio-active-stent (BAS) Stent and SYNERGYâ„¢ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
28 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
29 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
30 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
31 Comparative Effectiveness and Safety Analysis of Low-dose and Standard-dose Ticagrelor in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT03381755 Phase 4 half-dose ticagrelor;standard-dose ticagrelor
32 Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. Unknown status NCT02341729 Phase 4 ticagrelor
33 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
34 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
35 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
36 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
37 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
38 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimaxâ„¢) to the Drug (Everolimus) -Eluting Stent (Synergyâ„¢) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
39 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
40 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
41 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
42 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
43 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
44 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
45 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
46 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
47 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
48 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
49 "Impact of Cigarette Smoking on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With P2Y12 Inhibitors" - Trial COPTER - Unknown status NCT02026713 Phase 4
50 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepideâ„¢ Stent vs. Taxusâ„¢ Unknown status NCT00914420 Phase 4

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Sources

Genetic Tests for Ischemia

About this section
Sources

Anatomical Context for Ischemia

About this section

MalaCards organs/tissues related to Ischemia:

40
Endothelial, Bone Marrow, Heart, Spinal Cord, Bone, Liver, Brain
Sources

Publications for Ischemia

About this section

Articles related to Ischemia:

(show top 50) (show all 54100)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 61 54
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 61 54
20347937 2010
3
Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. 61 54
20107113 2010
4
Vascular responses to hypoxia and ischemia. 54 61
19729615 2010
5
Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. 61 54
19822191 2010
6
The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. 54 61
19932587 2010
7
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 61 54
20007348 2010
8
Selective intrarenal human A1 adenosine receptor overexpression reduces acute liver and kidney injury after hepatic ischemia reperfusion in mice. 61 54
20065944 2010
9
Effects of AMP-activated protein kinase in cerebral ischemia. 61 54
20010958 2010
10
Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. 61 54
20152804 2010
11
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 54 61
20222175 2010
12
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 54 61
20133634 2010
13
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 54 61
20190407 2010
14
Evidence for caspase effects on release of cytochrome c and AIF in a model of ischemia in cortical neurons. 61 54
19944742 2010
15
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 61 54
19850943 2009
16
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 61 54
19917352 2009
17
Up-regulation of ICAM-1 during cold ischemia triggers early neutrophil infiltration in human pancreas allograft reperfusion. 54 61
19917355 2009
18
Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats. 61 54
19482302 2009
19
Association of cystatin C with ischemia in patients with coronary heart disease. 61 54
19816865 2009
20
Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. 54 61
19862336 2009
21
Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. 54 61
19628785 2009
22
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 54 61
19622751 2009
23
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 61 54
19576596 2009
24
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 54 61
19682205 2009
25
Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. 61 54
19528256 2009
26
Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. 54 61
19344900 2009
27
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 54 61
19753114 2009
28
Lentiviral-mediated overexpression of Bcl-xL protects primary endothelial cells from ischemia/reperfusion injury-induced apoptosis. 54 61
19716047 2009
29
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. 61 54
19685518 2009
30
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 61 54
19596001 2009
31
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 61 54
19443639 2009
32
Ischemia/reperfusion Lung Injury Increases Serum Ferritin and Heme Oxygenase-1 in Rats. 61 54
19885035 2009
33
Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia. 54 61
19340019 2009
34
Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. 54 61
19333129 2009
35
Effects of overexpression of antioxidants on the release of cytochrome c and apoptosis-inducing factor in the model of ischemia. 61 54
19429031 2009
36
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 54 61
19371824 2009
37
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. 61 54
19094989 2009
38
Neutrophil elastase inhibitor attenuates hippocampal neuronal damage after transient forebrain ischemia in rats. 61 54
19168036 2009
39
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 54 61
19279473 2009
40
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. 54 61
19075097 2009
41
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 54 61
19028502 2009
42
[Biochemical markers in the diagnosis of acute coronary syndrome]. 61 54
19681456 2009
43
Plasma brain natriuretic peptide at rest and after adenosine-induced myocardial ischemia in normotensive and essential hypertensive patients with suspected coronary artery disease. 61 54
18951935 2009
44
Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. 61 54
19117950 2009
45
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 54 61
18812468 2009
46
Ischemia alters the expression of connexins in the aged human brain. 61 54
19794823 2009
47
Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs. 54 61
18976644 2009
48
Effect of ischemia/reperfusion on bladder nerve and detrusor cell damage. 54 61
18998234 2009
49
Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat. 54 61
18948146 2009
50
TEMPOL, a membrane-permeable radical scavenger, attenuates gastric mucosal damage induced by ischemia/reperfusion: a key role for superoxide anion. 54 61
19087872 2009